Replimune to Present at Two Upcoming Investor Conferences

WOBURN, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. REPL, a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members from the Replimune management team will participate in fireside chats and host investor meetings at the following two conferences.

Guggenheim Healthcare Talks Forum – Oncology Day 2020

Date: Thursday, February 13, 2020

Presentation Time: 2:30 pm ET

Location: St. Regis in New York, NY

9^th Annual SVB Leerink Global Healthcare Conference

Date: Tuesday, February 25, 2020

Presentation Time: 11:00 am ET

Location: Lotte New York Palace in New York, NY

About Replimune

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of "oncolytic immune-gene therapies" for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune's Immulytic^™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action. For more information, please visit www.replimune.com.

Investor Inquiries

Chris Brinzey

Westwicke, an ICR Company

339.970.2843

chris.brinzey@westwicke.com

Media Inquiries

Arleen Goldenberg

Verge Scientific Communications

917.548.1582

agoldenberg@vergescientific.com